Suzanne Lentzsch

NewYork–Presbyterian Hospital — United States

Medicine · Health Sciences

58h-index17.3kcitations499works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(314), Protein Degradation and Inhibitors(110), Amyloidosis: Diagnosis, Treatment, Outcomes(103), Peptidase Inhibition and Analysis(59), Chronic Lymphocytic Leukemia Research(47)

Publications498 total

CAR T-cells in multiple myeloma: the race to the start line
Bone Marrow Transplantation·2025
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
Hematology·2025· 1 citedOpen Access
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era
HemaSphere·2025Open Access
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia·2025· 2 citedOpen Access
Treatment response assessment using whole body diffusion weighted-magnetic resonance imaging in myeloma: a retrospective cohort study
Leukemia & lymphoma/Leukemia and lymphoma·2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Blood Cancer Journal·2025· 1 citedOpen Access
Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis
Blood·2025
Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma
Blood·2025Open Access
ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)
Blood·2025Open Access
Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial
Blood·2025Open Access
Long-term follow-up of venetoclax therapy in AL amyloidosis
Blood·2025
Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis
Blood·2025Open Access
Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy
Blood·2025
An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis
Blood·2025Open Access
Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems
Blood·2025Open Access
Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation
Blood·2025
Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study
Blood·2025Open Access
Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease
Blood·2025
Use of CD38 antibodies in high-risk newly diagnosed multiple myeloma – meta-analysis
2025Open Access
A35, a Novel Small Molecule Kinase Inhibitor, Shows High Efficacy in Multiple Myeloma and Overcomes IMiDs Resistance
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 25Next →

Frequent Co-authors

Brian G.M. Durie(15), Kenneth C. Anderson(14), Michèle Cavo(13), Meletios Α. Dimopoulos(12), Paul G. Richardson(11), Evangelos Terpos(10), S. Vincent Rajkumar(10), Jesús F. San Miguel(10), Markus Y. Mapara(10), Philippe Moreau(9), Sagar Lonial(9), Hartmut Goldschmidt(9), Elena Zamagni(9), Pieter Sonneveld(9), Saad Z. Usmani(8), Sundar Jagannath(8), Faith E. Davies(8), Noopur Raje(8), Shaji Kumar(7), Nikhil C. Munshi(7)